Navigation Links
nanoTox COO Greg King Advises Nanotech Companies to View Safety Concerns as an Opportunity to Gain Consumer Trust
Date:4/7/2010

nanoTox COO Greg King responded to the AOL News series, “The Nanotech Gamble,” with advice for nano-product companies on how to turn concerns over nanotechnology into consumer relations wins.

Austin, TX (Vocus) -- Responding to a series of AOL News articles questioning the oversight of nanotechnology product safety (http://www.aolnews.com/category/nanotech/), nanoTox COO Greg King said that nano-product companies will need to confront possible negative perceptions directly to avoid the kinds of public outcry experienced by bioengineered food companies in the past.

“It’s in people’s nature to fear the unknown,” said King. “And while companies may not be able to educate everyone in the complexities of nanotechnology, they can turn safety concerns to their advantage by being transparent about its use in their products, documenting their careful research and emphasizing concern over human and environment health.”

King was responding to AOL News and Pulitzer Prize-winning reporter Andrew Schneider, who published a series entitled “The Nanotech Gamble” which explored possible risks that may accompany nanotechnology research and product development. Schneider’s series was greeted with concern by most in the U.S. nanoproduct industry.

“Schneider’s articles expresses quite well the public’s concern about nanomaterials.” King added. “No new technology gains wide consumer acceptance until potential safety concerns are addressed and resolved.

“Companies wanting to successfully commercialize products that contain nanomaterials will need to address those safety concerns. This is especially true for nanoproducts that have direct human contact, such as textiles, foods, medicines, cosmetics, personal care products. The companies that can demonstrate that their products are safe will have a competitive advantage.”

King is the author of several articles on nanotechnology risk management and nanotechnology regulation. King’s company, nanoTox, is the first to provide complete risk assessment and solutions exclusively for nanoparticles.

“The nanotech revolution is one of the best opportunities for cosmetic, food, and other companies incorporating nanoparticles to build new trust with their existing and future customers,” said King. “By showing that they are ahead of the game, they can inoculate themselves against negative perceptions and even champion themselves as leaders in product safety.”

About nanoTox™, Inc.
nanoTox is the first company to provide complete risk assessment – and solutions – exclusively for nanoparticles. nanoTox can help companies commercialize their products by helping address safety issues and responding to regulatory requirements.

nanoTox determines the toxicity of its clients’ nanoproducts and offers strategies for managing, reducing or eliminating risk to meet state and federal safety guidelines and shorten time to market. Because nanoTox uses methodologies that are performed under recognized international data quality standards (GLP, ISO, etc.) in its laboratories, the results and associated assessments are suitable for use to support regulatory decisions, product registrations, litigation and for acceptance by the insurance industry.

nanoTox ensures complete client confidentiality for all of its clients, which include companies or entities that require government approval to market their nanoproducts, venture capital firms that invest in nanoproduct companies, law firms engaged by such companies and insurance companies considering insuring such companies from liability. For more information, visit www.nanotox.com.

###

Read the full story at http://www.prweb.com/releases/2010/04/prweb3846944.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. Burrill Merchant Banking Advises NPS on Phase III Licensing Agreement
2. Burrill Merchant Banking Advises Faes Farma on Bilastine Licensing Agreement
3. White Paper Advises Pharma Manufacturers on How to Select an Aseptic Fill/Finish Contractor, Avoid the Most Common Mistakes
4. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
5. Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc
6. KTA Capital Advises SpringTree Global Investors on an AU$25.5 Million Investment in Prima BioMed Ltd
7. Stevens to host Nanoscience/Nanotechnology & Corrosion symposium, Nov. 13
8. NASA technology forms the basis for a new nanotechnology company
9. Superbugs, shapes and nanotechnology
10. Siemens and Xintek Form Joint Venture to Develop Nanotechnology-Enabled Multi-Pixel X-ray Tubes
11. Nanotech could make solar energy as easy and cheap as growing grass
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Soligenix, Inc. (OTCQB: ... company focused on developing and commercializing products to ... medical need, announced today the long-term follow-up data ... (dusquetide), a first-in-class Innate Defense Regulator (IDR), in ... and neck cancer patients undergoing chemoradiation therapy (CRT).  ...
(Date:12/8/2016)... Dec. 8, 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: ... develops and plans to commercialize innovative therapeutics for ... common stock were approved for trading on the ... on the OTCQX, effective today, under the ticker ... OTCQX market, companies must meet high financial standards, ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. ... billion KRW (US $18.9M) Series A financing. This financing ... G.N. Tech Venture and SNU Bio Angel. This new ... 30.5 billion KRW (US $27.7M) since its founding in ... to bolster the development and commercialization of its immuno-oncology ...
(Date:12/8/2016)... 8, 2016   Biocept, Inc . (NASDAQ: ... of clinically actionable liquid biopsy tests to improve ... data featuring its Target Selectorâ„¢ Circulating Tumor Cell ... the detection of actionable biomarkers in patients with ... by Sara Cannon Research Institute (SCRI), the research ...
Breaking Biology Technology:
(Date:12/7/2016)... December 7, 2016 BioCatch , the global ... its patent portfolio, which grew to over 40 granted and pending patents. ... , , ... patent entitled " System, Device, and Method Estimating Force Applied ... device makers to forego costly hardware components needed to estimate the force ...
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... priced an offering of €500.0 million principal amount of its ... amount of its 2.425% senior unsecured notes due 2026. ... occur on December 13, 2016, subject to the satisfaction of customary ... basis. The Company intends to ...
(Date:12/5/2016)... -- The Office of Justice Programs, National Institute of ... or Replace Medico Legal Autopsies?" on NIJ.gov.  The ... forensic autopsies with postmortem X-ray computed tomography, commonly ... to recommendations made by The National Academy of ... a potential component of medicolegal death investigations. NIJ,s ...
Breaking Biology News(10 mins):